Serum NDRG2 acts as a novel biomarker for the diagnosis of patients with gastric cancer

血清NDRG2可作为胃癌患者诊断的新型生物标志物

阅读:3
作者:Gang Wang,Bo Yang,Liangliang Wu,Ting Jin,Qiyan Wu,Lijun Zhang,Lingxiong Wang,Chunxi Liu,Tianyi Liu,Shunchang Jiao

Abstract

Background: Gastric cancer (GC) is one of the most common digestive malignancies worldwide. N-myc downstream-regulated gene 2 (NDRG2) is a differentiation-related gene which is considered to be a metastasis suppressor gene. The purpose of this study was to detect the serum expression of NDRG2 and its clinical significance in the early detection of patients with GC. Methods: Serum NDRG2 expression were examined in 107 patients with GC, 52 with benign gastric disease patients, and 64 healthy volunteers using reverse transcription quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analysis at mRNA and protein level, respectively. The relationship between NDRG2 expression and clinicopathologic characteristics was analyzed by chi-square test. The diagnostic value of NDRG2 was estimated via establishing the receiver operating characteristic (ROC) curve. Results: the serum NDRG2 expression was lower in GC patients than that in patients with benign disease and healthy volunteers both at mRNA and protein level (P<0.05). And the low NDRG2 expression was significantly associated with tumor size, lymph node metastasis and TNM stage. ROC curve manifested that NDRG2 had a high diagnostic value with an AUC of 0.896 corresponding with a sensitivity of 85.9% and a specificity of 62.6%. Conclusion: The expression of NDRG2 was reduced in GC patients. Moreover, serum NDRG2 could be a potential diagnostic marker for GC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。